Search Results

You are looking at 1 - 10 of 122 items for :

  • "sunitinib" x
  • Refine by Access: All x
Clear All
Full access

George D. Demetri, Margaret von Mehren, Cristina R. Antonescu, Ronald P. DeMatteo, Kristen N. Ganjoo, Robert G. Maki, Peter W.T. Pisters, Chandrajit P. Raut, Richard F. Riedel, Scott Schuetze, Hema M. Sundar, Jonathan C. Trent, and Jeffrey D. Wayne

117) or platelet-derived growth factor receptor alpha (PDGFRA). The standard of care in the management of patients with GIST rapidly changed after the introduction of tyrosine kinase inhibitors (TKIs), such as imatinib mesylate and sunitinib malate

Full access

Tarek Haykal, Babikir Kheiri, Varun Samji, Yazan Zayed, Ragheed Al-Dulaimi, Inderdeep Gakhal, Areeg Bala, Jason Sotzen, Ahmed Abdalla, and Ghassan Bachuwa

Background: Metastatic clear-cell renal cell carcinoma (RCC) is largely incurable, and its treatment remains challenging. Sunitinib, a tyrosine kinase inhibitor, is one of the current standard-of-care options for treatment-naïve patients with

Full access

Daniel Y. C. Heng and Toni K. Choueiri

TE Tomczak P . Sunitinib versus interferon alfa in metastatic renal-cell carcinoma . N Engl J Med 2007 ; 356 : 115 – 124 . 15 Escudier B Eisen T Stadler WM . Sorafenib in advanced clear-cell renal-cell carcinoma . N Engl J Med 2007

Full access

George D. Demetri, Robert S. Benjamin, Charles D. Blanke, Jean-Yves Blay, Paolo Casali, Haesun Choi, Christopher L. Corless, Maria Debiec-Rychter, Ronald P. DeMatteo, David S. Ettinger, George A. Fisher, Christopher D. M. Fletcher, Alessandro Gronchi, Peter Hohenberger, Miranda Hughes, Heikki Joensuu, Ian Judson, Axel Le Cesne, Robert G. Maki, Michael Morse, Alberto S. Pappo, Peter W. T. Pisters, Chandrajit P. Raut, Peter Reichardt, Douglas S. Tyler, Annick D. Van den Abbeele, Margaret von Mehren, Jeffrey D. Wayne, and John Zalcberg

for GISTs rapidly changed after the introduction of effective molecularly targeted therapy (such as imatinib and sunitinib). Because of these changes, the NCCN organized a multidisciplinary panel composed of experts in medical oncology, molecular

Full access

Eric Jonasch

and PROTECT trials both showed negative results. 1 , 2 ASSURE evaluated 1 year of adjuvant sunitinib versus 1 year of adjuvant sorafenib versus placebo and found no significant difference in disease-free survival (DFS) among all 3 arms, with more

Full access

Margaret von Mehren, R. Lor Randall, Robert S. Benjamin, Sarah Boles, Marilyn M. Bui, Ephraim S. Casper, Ernest U. Conrad III, Thomas F. DeLaney, Kristen N. Ganjoo, Suzanne George, Ricardo J. Gonzalez, Martin J. Heslin, John M. Kane III, Joel Mayerson, Sean V. McGarry, Christian Meyer, Richard J. O’Donnell, Alberto S. Pappo, I. Benjamin Paz, John D. Pfeifer, Richard F. Riedel, Scott Schuetze, Karen D. Schupak, Herbert S. Schwartz, Brian A. Van Tine, Jeffrey D. Wayne, Mary Anne Bergman, and Hema Sundar

Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. The introduction of KIT and PDGFRα inhibitors such as imatinib and sunitinib has significantly improved the outcomes in patients with

Full access

Eric Jonasch

in Oncology (NCCN Guidelines) for Kidney Cancer. Adjuvant Therapy Three trials have been conducted in the adjuvant setting, 2 of which (ASSURE and PROTECT) showed negative results for adjuvant sunitinib, sorafenib, and pazopanib. A third trial

Full access

Toni K. Choueiri

further inform on this question by evaluating outcomes after nephrectomy plus sunitinib versus sunitinib alone. Prognosis Risk factors associated with prognosis irrespective of type of treatment include time from diagnosis to treatment, hemoglobin

Full access

Christopher E. Desch

(sunitinib malate) capsules US fact sheet . Available at : http://www.pfizer.com/pfizer/download/news/asco/sutent_fact_sheet.pdf . Accessed June 26, 2006 . 3. American Cancer Society . Medicare Part D: what you need to know about the new drug

Full access

Irbaz Bin Riaz, Saad Ullah Malik, Muhammad Husnain, Qurat Ul Ain Riaz Sipra, Warda Faridi, Farva R. Gondal, Thanh Ho, Siddhartha Yadav, Zhen Wang, and Manish Kohli

. Methods: Literature search was done using Medline, CENTRAL, and Embase. The DerSimonian and Laird random effects model was used to pool estimates for DFS, OS, and common side effects across the 4 trials. A subgroup analysis was performed for sunitinib